DOCSLIB.ORG

A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection CLINICAL RESEARCH www.jasn.org A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection Weijia Zhang,1 Zhengzi Yi,1 Karen L. Keung,2 Huimin Shang,3 Chengguo Wei,1 Paolo Cravedi,1 Zeguo Sun,1 Caixia Xi,1 Christopher Woytovich,1 Samira Farouk,1 Weiqing Huang,1 Khadija Banu,1 Lorenzo Gallon,4 Ciara N. Magee,5 Nader Najafian,5 Milagros Samaniego,6 Arjang Djamali ,7 Stephen I. Alexander,2 Ivy A. Rosales,8 Rex Neal Smith,8 Jenny Xiang,3 Evelyne Lerut,9 Dirk Kuypers,10,11 Maarten Naesens ,10,11 Philip J. O’Connell,2 Robert Colvin,8 Madhav C. Menon,1 and Barbara Murphy1 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background In kidney transplant recipients, surveillance biopsies can reveal, despite stable graft function, histologic features of acute rejection and borderline changes that are associated with undesirable graft outcomes. Noninvasive biomarkers of subclinical acute rejection are needed to avoid the risks and costs associated with repeated biopsies. Methods We examined subclinical histologic and functional changes in kidney transplant recipients from the prospective Genomics of Chronic Allograft Rejection (GoCAR) study who underwent surveillance biopsies over 2 years, identifying those with subclinical or borderline acute cellular rejection (ACR) at 3 months (ACR-3) post-transplant. We performed RNA sequencing on whole blood collected from 88 indi- viduals at the time of 3-month surveillance biopsy to identify transcripts associated with ACR-3, developed a novel sequencing-based targeted expression assay, and validated this gene signature in an independent cohort. Results Study participants with ACR-3 had significantly higher risk than those without ACR-3 of subse- quent clinical acute rejection at 12 and 24 months, faster decline in graft function, and decreased graft survival in adjusted Cox analysis. We identified a 17-gene signature in peripheral blood that accurately diagnosed ACR-3, and validated it using microarray expression profiles of blood samples from 65 trans- plant recipients in the GoCAR cohort and three public microarray datasets. In an independent cohort of 110 transplant recipients, tests of the targeted expression assay on the basis of the 17-gene set showed that it identified individuals at higher risk of ongoing acute rejection and future graft loss. Conclusions Our targeted expression assay enabled noninvasive diagnosis of subclinical acute rejection and inflammation in the graft and may represent a useful tool to risk-stratify kidney transplant recipients. JASN 30: ccc–ccc, 2019. doi: https://doi.org/10.1681/ASN.2018111098 Kidney transplantation is the therapy of choice for ESRD. Although short-term allograft outcomes Received November 8, 2018. Accepted May 1, 2019. including clinical acute rejection episodes (i.e., occurring in the presence of graft dysfunction) Published online ahead of print. Publication date available at www.jasn.org. have declined over past decades, proportionate im- provement in long-term allograft survival remains Correspondence: Dr. Barbara Murphy, Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount 1–3 unrealized. The rates of clinically detected epi- Sinai, One Gustave L Levy Place, Box 1243, New York, NY 10029. sodes of acute rejection within the first year in the Email: [email protected] modern tacrolimus/mycophenolate era are ,10% Copyright © 2019 by the American Society of Nephrology JASN 30: ccc–ccc,2019 ISSN : 1046-6673/3008-ccc 1 CLINICAL RESEARCH www.jasn.org among adult kidney recipients in the United States.2 The effect Significance Statement of these episodes on long-term graft survival is variable, de- pending on the severity of episode, time from transplantation, Biomarkers for noninvasive diagnosis of subclinical acute rejection and effective treatment of these episodes with return of creat- are needed to enable risk-stratification and tailoring of immuno- inine to prerejection baseline.4 suppression for kidney transplant recipients. Using RNA sequencing fl analyses of whole blood collected from a cohort of transplant re- Graft in ammation, however, may also occur initially in the cipients at the time of surveillance biopsy, the authors identified a absence of graft function decline. The wide prevalence of sub- transcriptional signature on the basis of a set of 17 genes that ac- clinical rejection, i.e., lymphocytic tubulitis and interstitial in- curately detects ongoing subclinical rejection. After extensive val- flammation in early surveillance biopsy specimens, and its idation, they developed a sequencing-based targeted expression effect on long-term allograft histology, function, and survival assay on the basis of this gene set that was able to identify subclinical rejection at 3 months post-transplant and increased risk of graft loss 5–10 has been appreciated only recently. The effect of milder in an independent cohort of 110 patients. This assay represents a subclinical inflammation, i.e., suspicious or borderline le- potentially useful tool to monitor kidney transplant recipients and sions, on allograft outcomes is even less characterized.11 optimize immunosuppressive therapy, although larger studies are In current clinical practice, the diagnosis of either clinical or needed to validate the assay’s clinical utility. subclinical allograft rejection requires a biopsy, a procedure burdened by clinical risks and costs. To obviate these issues, readings .1000 were taken as positive. The surveillance biopsy fi prior studies have tested noninvasive pro ling of urinary pro- specimens in the patients in the Belgian cohort were taken at the 12,13 14–16 teins and blood transcriptomic signatures, but results same time points (3, 6, 12, and 24 months) as for the GoCAR have been inconsistent so far. An assay that could be used in cohort. Highly sensitized patients requiring desensitization were clinical practice for the purpose of accurately diagnosing sub- excluded from the GoCAR study and not present in the Belgium clinical rejection offers the potential to identify and treat un- cohort. We used United Network for Organ Sharing and The derlying subclinical rejection without the need for a biopsy. Australia and New Zealand Dialysis and Transplant Registry da- Herein, we examined the incidence of subclinical rejection tabases to determine long-term outcomes for the GoCAR and borderline lesions over time in the Genomics of Chronic enrollees. Allograft Rejection study (GoCAR), a prospective, multicenter center study in which kidney transplant recipients underwent Genomic Experiments and Data Analysis serial surveillance biopsies. We determined the effect of sub- The details regarding genomic experiments (RNA sequencing, clinical graft inflammation on allograft function and survival, microarray, and targeted RNA expression [TREx] assay) are and developed a clinically applicable assay that detects sub- provided in the Supplemental Material and the data analysis clinical acute rejection by measuring the transcriptome in pe- workflow is depicted in Supplemental Figure 1. Briefly, mRNA ripheral blood. sequencing (Illumina HiSeq4000 sequencer) was performed on 88 samples obtained at 3 months post-transplant in the GoCAR cohort as discovery set for identification of gene sig- METHODS natures associated with ACR-3. After read quality control, mapping, and normalization steps on the raw sequencing Patients reads, the expression data were compared between ACR-3 The study included participants of the GoCAR study and kidney and non-ACR at 3 months (NACR-3), with both induction transplant recipients prospectively followed-up at the University therapy and deceased donor as confounders, to identify dif- Hospitals Leuven, Leuven, Belgium. The GoCAR study is a pro- ferentially expressed genes (DEGs) with a P value ,0.05 using spective,multicenterstudy(UnitedStatesandAustralia)aimedat unpaired LIMMA test,20 a linear model to assess differential investigating the genetics and genomics associated with the de- gene expression in the context of multiple variables. The DEGs velopment of allograft rejection or injury in kidney transplant were then subjected to enrichment analysis for canonical recipients. Patients underwent surveillance biopsies pretrans- pathway, gene ontology, and immune cell types to identify plant (before implantation), and at 3, 6, 12, and 24 months after classes or groups of genes that were associated with ACR. transplant. Patients were followed up for at least 5 years or until Next, a more focused gene set associated with ACR-3 was death. The details of patient enrollment criteria and study design identified from the DEGs using a randomization approach have been previously described.17,18 All biopsy specimens were described previously.18. An optimal gene set with the highest reported for Banff component scores by a central core laboratory AUC (area under the receiver operating characteristic curve) at Massachusetts General Hospital. The diagnosis of acute cel- score for diagnosis of ACR-3 was then determined by fitting a lular rejection (ACR) at 3 months (ACR-3) was made by apply- penalized logistic regression model on the expression data of ing Banff 2013 Classification19 on all clinically indicated and the focus gene set following a 5000-iterations methodology18 surveillance biopsy samples and included borderline subclinical (Supplemental Material). The AUC for the final gene set was rejection. Donor-specific anti-HLA antibodies (DSAs) were crossvalidated
Load more

Recommended publications
  • Allele-Specific Expression of Ribosomal Protein Genes in Interspecific Hybrid Catfish
    Allele-specific Expression of Ribosomal Protein Genes in Interspecific Hybrid Catfish by Ailu Chen A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Auburn, Alabama August 1, 2015 Keywords: catfish, interspecific hybrids, allele-specific expression, ribosomal protein Copyright 2015 by Ailu Chen Approved by Zhanjiang Liu, Chair, Professor, School of Fisheries, Aquaculture and Aquatic Sciences Nannan Liu, Professor, Entomology and Plant Pathology Eric Peatman, Associate Professor, School of Fisheries, Aquaculture and Aquatic Sciences Aaron M. Rashotte, Associate Professor, Biological Sciences Abstract Interspecific hybridization results in a vast reservoir of allelic variations, which may potentially contribute to phenotypical enhancement in the hybrids. Whether the allelic variations are related to the downstream phenotypic differences of interspecific hybrid is still an open question. The recently developed genome-wide allele-specific approaches that harness high- throughput sequencing technology allow direct quantification of allelic variations and gene expression patterns. In this work, I investigated allele-specific expression (ASE) pattern using RNA-Seq datasets generated from interspecific catfish hybrids. The objective of the study is to determine the ASE genes and pathways in which they are involved. Specifically, my study investigated ASE-SNPs, ASE-genes, parent-of-origins of ASE allele and how ASE would possibly contribute to heterosis. My data showed that ASE was operating in the interspecific catfish system. Of the 66,251 and 177,841 SNPs identified from the datasets of the liver and gill, 5,420 (8.2%) and 13,390 (7.5%) SNPs were identified as significant ASE-SNPs, respectively.
    [Show full text]
  • Transcriptomic Analysis of the Aquaporin (AQP) Gene Family
    Pancreatology 19 (2019) 436e442 Contents lists available at ScienceDirect Pancreatology journal homepage: www.elsevier.com/locate/pan Transcriptomic analysis of the Aquaporin (AQP) gene family interactome identifies a molecular panel of four prognostic markers in patients with pancreatic ductal adenocarcinoma Dimitrios E. Magouliotis a, b, Vasiliki S. Tasiopoulou c, Konstantinos Dimas d, * Nikos Sakellaridis d, Konstantina A. Svokos e, Alexis A. Svokos f, Dimitris Zacharoulis b, a Division of Surgery and Interventional Science, Faculty of Medical Sciences, UCL, London, UK b Department of Surgery, University of Thessaly, Biopolis, Larissa, Greece c Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece d Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece e The Warren Alpert Medical School of Brown University, Providence, RI, USA f Riverside Regional Medical Center, Newport News, VA, USA article info abstract Article history: Background: This study aimed to assess the differential gene expression of aquaporin (AQP) gene family Received 14 October 2018 interactome in pancreatic ductal adenocarcinoma (PDAC) using data mining techniques to identify novel Received in revised form candidate genes intervening in the pathogenicity of PDAC. 29 January 2019 Method: Transcriptome data mining techniques were used in order to construct the interactome of the Accepted 9 February 2019 AQP gene family and to determine which genes members are differentially expressed in PDAC as Available online 11 February 2019 compared to controls. The same techniques were used in order to evaluate the potential prognostic role of the differentially expressed genes. Keywords: PDAC Results: Transcriptome microarray data of four GEO datasets were incorporated, including 142 primary Aquaporin tumor samples and 104 normal pancreatic tissue samples.
    [Show full text]
  • Arcn1 (NM 145985) Mouse Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP508216 Arcn1 (NM_145985) Mouse Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Purified recombinant protein of Mouse archain 1 (Arcn1), with C-terminal MYC/DDK tag, expressed in HEK293T cells, 20ug Species: Mouse Expression Host: HEK293T Tag: C-MYC/DDK Predicted MW: 57.7 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. Storage: Store at -80°C after receiving vials. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_666097 Locus ID: 213827 UniProt ID: Q5XJY5 RefSeq Size: 3470 Cytogenetics: 9 A5.2 RefSeq ORF: 1536 Synonyms: 4632432M07Rik; nur17 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Arcn1 (NM_145985) Mouse Recombinant Protein – TP508216 Summary: The coatomer is a cytosolic protein complex that binds to dilysine motifs and reversibly associates with Golgi non-clathrin-coated vesicles, which further mediate biosynthetic protein transport from the ER, via the Golgi up to the trans Golgi network. Coatomer complex is required for budding from Golgi membranes, and is essential for the retrograde Golgi-to-ER transport of dilysine-tagged proteins.
    [Show full text]
  • Global Analysis of Methionine Oxidation Provides a Census Of
    bioRxiv preprint doi: https://doi.org/10.1101/467290; this version posted January 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Global analysis of methionine oxidation provides a census of folding stabilities for the human proteome Ethan J. Walker1,2, John Q. Bettinger1, Kevin A. Welle3, Jennifer R. Hryhorenko3, Sina Ghaemmaghami1,3* 1Department of Biology, University of Rochester, NY, 14627, USA 2Department of Biochemistry, University of Rochester Medical Center, NY, 14627, USA 3University of Rochester Mass Spectrometry Resource Laboratory, NY, 14627, USA *Correspondence: [email protected] (S.G.) 1 bioRxiv preprint doi: https://doi.org/10.1101/467290; this version posted January 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. ABSTRACT The stability of proteins influences their tendency to aggregate, undergo degradation or become modified in cells. Despite their significance to understanding protein folding and function, quantitative analyses of thermodynamic stabilities have been mostly limited to soluble proteins in purified systems. We have used a highly multiplexed proteomics approach, based on analyses of methionine oxidation rates, to quantify stabilities of ~10,000 unique regions within ~3,000 proteins in human cell extracts. The data identify lysosomal and extracellular proteins as the most stable ontological subsets of the proteome.
    [Show full text]
  • Redefining the Specificity of Phosphoinositide-Binding by Human
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.20.163253; this version posted June 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Redefining the specificity of phosphoinositide-binding by human PH domain-containing proteins Nilmani Singh1†, Adriana Reyes-Ordoñez1†, Michael A. Compagnone1, Jesus F. Moreno Castillo1, Benjamin J. Leslie2, Taekjip Ha2,3,4,5, Jie Chen1* 1Department of Cell & Developmental Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801; 2Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205; 3Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218; 4Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205; 5Howard Hughes Medical Institute, Baltimore, MD 21205, USA †These authors contributed equally to this work. *Correspondence: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/2020.06.20.163253; this version posted June 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. ABSTRACT Pleckstrin homology (PH) domains are presumed to bind phosphoinositides (PIPs), but specific interaction with and regulation by PIPs for most PH domain-containing proteins are unclear. Here we employed a single-molecule pulldown assay to study interactions of lipid vesicles with full-length proteins in mammalian whole cell lysates.
    [Show full text]
  • Formation of COPI-Coated Vesicles at a Glance Eric C
    © 2018. Published by The Company of Biologists Ltd | Journal of Cell Science (2018) 131, jcs209890. doi:10.1242/jcs.209890 CELL SCIENCE AT A GLANCE Formation of COPI-coated vesicles at a glance Eric C. Arakel1 and Blanche Schwappach1,2,* ABSTRACT unresolved, this review attempts to refocus the perspectives of The coat protein complex I (COPI) allows the precise sorting of lipids the field. and proteins between Golgi cisternae and retrieval from the Golgi KEY WORDS: Arf1, ArfGAP, COPI, Coatomer, Golgi, Endoplasmic to the ER. This essential role maintains the identity of the early reticulum, Vesicle coat secretory pathway and impinges on key cellular processes, such as protein quality control. In this Cell Science at a Glance and accompanying poster, we illustrate the different stages of COPI- Introduction coated vesicle formation and revisit decades of research in the Vesicle coat proteins, such as the archetypal clathrin and the coat context of recent advances in the elucidation of COPI coat structure. protein complexes II and I (COPII and COPI, respectively) are By calling attention to an array of questions that have remained molecular machines with two central roles: enabling vesicle formation, and selecting protein and lipid cargo to be packaged within them. Thus, coat proteins fulfil a central role in the 1Department of Molecular Biology, Universitätsmedizin Göttingen, Humboldtallee homeostasis of the cell’s endomembrane system and are the basis 23, 37073 Göttingen, Germany. 2Max-Planck Institute for Biophysical Chemistry, 37077 Göttingen, Germany. of functionally segregated compartments. COPI operates in retrieval from the Golgi to the endoplasmic reticulum (ER) and in intra-Golgi *Author for correspondence ([email protected]) transport (Beck et al., 2009; Duden, 2003; Lee et al., 2004a; Spang, E.C.A., 0000-0001-7716-7149; B.S., 0000-0003-0225-6432 2009), and maintains ER- and Golgi-resident chaperones and enzymes where they belong.
    [Show full text]
  • Targeting PH Domain Proteins for Cancer Therapy
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Supplemental Figure 2.Eps
    Androgen Resveratrol 75uM 150uM 43h-10nM 43h-100nM 43h-1uM 20h-10uM 18h-25uM 20h-40uM 20h-100uM 0h 1h 3h 6h 9h 12h 15h 18h 21h 24h 48h 60h 0h 1h 2h 3h 4h 6h 8h 12h 14h 16h 18h 20h 22h 24h 48h 60h 7h-R1881 9h-R1881 18h-R1881 24h-R1881 50h-R1881 72h-R1881 18h-DHT10 50h-DHT10 24h-DHT100 24h-DHT1000 46h-noR1881 70h-noR1881 99855 ZFH4 zinc finger homeodomain 4 Hs.109314 105366 NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 p105 Hs.83428 112015 SEPT6 septin 6 Hs.90998 111438 SLC12A2 **solute carrier family 12 sodium/potassium/chloride transporters, member 2 Hs.110736 117460 ZIC2 Zic family member 2 odd-paired homolog, Drosophila Hs.132863 112768 KIAA0914 KIAA0914 gene product Hs.177664 111066 ESTs, Weakly similar to GNMSLL retrovirus-related reverse transcriptase homolog - mouse retrotransposon [M.musculus] Hs.301451 104992 FN1 fibronectin 1 Hs.287820 116170 RDC1 G protein-coupled receptor Hs.23016 99709 PDCD5 programmed cell death 5 Hs.166468 112624 CTBP1 C-terminal binding protein 1 Hs.239737 118259 GRB10 growth factor receptor-bound protein 10 Hs.81875 111378 PURA purine-rich element binding protein A Hs.29117 120755 **ESTs, Weakly similar to CNG1_HUMAN cGMP-gated cation channel alpha 1 CNG channel alpha 1 CNG-1 CNG1 Cyclic nucleotide gated channel alpha 1 Cyclic nucleotide gated channel, photoreceptor Hs.356525 118729 DKFZP564D0462 hypothetical protein DKFZp564D0462 Hs.44197 101077 LRBA vesicle trafficking, beach and anchor containing Hs.62354 116608 BTD biotinidase Hs.78885 107627 BCHE butyrylcholinesterase
    [Show full text]
  • King's Research Portal
    King’s Research Portal DOI: 10.1016/j.ajhg.2016.06.011 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Izumi, K., Brett, M., Nishi, E., Drunat, S., Tan, E-S., Fujiki, K., Lebon, S., Cham, B., Masuda, K., Arakawa, M., Jacquinet, A., Yamazumi, Y., Chen, S-T., Verloes, A., Okada, Y., Katou, Y., Nakamura, T., Akiyama, T., Gressens, P., ... Shirahige, K. (2016). ARCN1 Mutations Cause a Recognizable Craniofacial Syndrome Due to COPI-Mediated Transport Defects. American Journal of Human Genetics, 99(2), 451–459. https://doi.org/10.1016/j.ajhg.2016.06.011 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Mouse Osbpl8 Conditional Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Osbpl8 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Osbpl8 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Osbpl8 gene (NCBI Reference Sequence: NM_175489 ; Ensembl: ENSMUSG00000020189 ) is located on Mouse chromosome 10. 24 exons are identified, with the ATG start codon in exon 2 and the TAG stop codon in exon 24 (Transcript: ENSMUST00000105275). Exon 5 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Osbpl8 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-456P17 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a gene trap allele exhibit elevated of HDL and gender-specific alterations in lipid metabolism. Exon 5 starts from about 8.17% of the coding region. The knockout of Exon 5 will result in frameshift of the gene. The size of intron 4 for 5'-loxP site insertion: 21997 bp, and the size of intron 5 for 3'-loxP site insertion: 7421 bp. The size of effective cKO region: ~571 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 5 24 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Osbpl8 Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.873,482 B2 Stefanon Et Al
    US007873482B2 (12) United States Patent (10) Patent No.: US 7.873,482 B2 Stefanon et al. (45) Date of Patent: Jan. 18, 2011 (54) DIAGNOSTIC SYSTEM FOR SELECTING 6,358,546 B1 3/2002 Bebiak et al. NUTRITION AND PHARMACOLOGICAL 6,493,641 B1 12/2002 Singh et al. PRODUCTS FOR ANIMALS 6,537,213 B2 3/2003 Dodds (76) Inventors: Bruno Stefanon, via Zilli, 51/A/3, Martignacco (IT) 33035: W. Jean Dodds, 938 Stanford St., Santa Monica, (Continued) CA (US) 90403 FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 WO WO99-67642 A2 12/1999 U.S.C. 154(b) by 158 days. (21)21) Appl. NoNo.: 12/316,8249 (Continued) (65) Prior Publication Data Swanson, et al., “Nutritional Genomics: Implication for Companion Animals'. The American Society for Nutritional Sciences, (2003).J. US 2010/O15301.6 A1 Jun. 17, 2010 Nutr. 133:3033-3040 (18 pages). (51) Int. Cl. (Continued) G06F 9/00 (2006.01) (52) U.S. Cl. ........................................................ 702/19 Primary Examiner—Edward Raymond (58) Field of Classification Search ................... 702/19 (74) Attorney, Agent, or Firm Greenberg Traurig, LLP 702/23, 182–185 See application file for complete search history. (57) ABSTRACT (56) References Cited An analysis of the profile of a non-human animal comprises: U.S. PATENT DOCUMENTS a) providing a genotypic database to the species of the non 3,995,019 A 1 1/1976 Jerome human animal Subject or a selected group of the species; b) 5,691,157 A 1 1/1997 Gong et al.
    [Show full text]